目的探讨Ⅰ型胶原羧基端前肽(PICP)和β胶原降解产物(β-CTx)在乳腺癌骨转移诊断和随访中的应用价值。方法将114例乳腺癌患者分为骨转移组(56例)和无骨转移组(对照组,58例)。对照组根据腋窝淋巴结转移情况分为p N0组(12例)、p N1组(15例)、p N2组(19例)和p N3组(12例),根据激素受体情况分为Lumina型组(30例)和非Lumina型组(28例)。分别测定114例患者血清中PICP和β-CTx的水平。结果骨转移组PICP和β-CTx的水平均高于对照组,差异有统计学意义(P<0.05)。对照组中,p N0组、p N1组、p N2组以及p N3组间的PICP和β-CTx水平比较,差异无统计学意义(P>0.05);非Lumina型组的PICP和β-CTx水平高于Lumina型组,差异有统计学意义(P<0.05)。对照组患者有7例无症状患者在随访过程中出现骨代谢指标异常升高,进一步检查发现有5例出现骨转移。结论骨代谢指标能够早于常规影像学检查提示骨转移的发生,在乳腺癌骨转移的诊断和远期随访中具有重要价值。 Objective To investigate the value of type Ⅰ collagen carboxyterminal propeptide (PICP) and β-collagen degradation product (β-CTx) in the diagnosis and follow-up of breast cancer with bone metastases. Methods 114 patients with breast cancer were divided into bone metastasis group (56 cases) and no bone metastasis group (control group, 58 cases). The control group was divided into pN0 group (n = 12), p N1 group (n = 15), p N2 group (n = 19) and pN3 group (n = 12) according to axillary lymph node metastasis. According to the hormone receptor status, Group (30 cases) and non-Lumina type group (28 cases). The serum levels of PICP and β-CTx in 114 patients were measured. Results The levels of PICP and β-CTx in the bone metastasis group were significantly higher than those in the control group (P <0.05). There was no significant difference in the levels of PICP and β-CTx between pN0, p N1, p N2 and pN3 in the control group (P> 0.05). The PICP and β-CTx in non-Lumina group The level was higher than Lumina type group, the difference was statistically significant (P <0.05). In the control group, 7 asymptomatic patients showed an abnormal increase of bone metabolism index during follow-up, and further examination revealed 5 cases of bone metastasis. Conclusion The indexes of bone metabolism can indicate the occurrence of bone metastasis earlier than routine imaging examination, which is of great value in the diagnosis and long-term follow-up of breast cancer with bone metastasis.